Dr. Reddy’s Laboratories is set to expand its collaboration with Sanofi Healthcare India (SHIPL) by launching the novel drug Beyfortus (nirsevimab) in India, a move that reinforces its commitment to strengthening the country’s immunisation landscape. Beyfortus, a prefilled injection containing the monoclonal antibody nirsevimab, is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants during or entering their first RSV season.

Under the agreement, Dr. Reddy’s will receive exclusive rights from SHIPL to promote and distribute Beyfortus across India. This announcement follows the exclusive distribution partnership Dr. Reddy’s entered last year for Sanofi’s vaccine portfolio in India. The launch of Beyfortus is expected in the second quarter of the current fiscal year, according to the Hyderabad-based pharmaceutical major.

RSV is a highly contagious virus that poses a serious threat to infants, being the leading cause of LRTD such as bronchiolitis and pneumonia. It is also a major reason for infant hospitalisations globally, even among healthy, full-term newborns. According to Dr. Reddy’s, in 2019 alone, RSV accounted for approximately 33 million cases of acute lower respiratory infections worldwide, over 3 million hospitalisations, and an estimated 26,300 in-hospital deaths of children under the age of five.

Also Read :- HaystackAnalytics Secures NABL Accreditation, Strengthening Clinical Genomics

M.V. Ramana, CEO – Branded Markets (India and Emerging Markets) at Dr. Reddy’s, highlighted that the addition of Beyfortus to the company’s portfolio will significantly bolster its immunisation offerings in India. Beyfortus has already received marketing authorisation in major global markets including the EU, U.S., China, and Japan, and was approved in India by the Central Drugs Standard Control Organization (CDSCO) in June.

“In India, where the disease burden is significant and early protection is critical, this collaboration with Dr. Reddy’s enables us to reach parents and healthcare providers with an innovative solution,” said Nitya Padmanabhan, Head of Sanofi Vaccines (India).

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!